Somensi Lincon Bordignon, Costa Philipe, Boeing Thaise, Bolda Mariano Luísa Nathália, de Gregório Elizama, E Silva Aline Teixeira Maciel, Longo Bruna, Locatelli Claudriana, de Souza Priscila, Magalhães Cássia Gonçalves, Pains Duarte Lucienir, da Silva Luisa Mota
Programa de Pós-Graduação em Desenvolvimento e Sociedade (PPGDS), Universidade Alto Vale do Rio do Peixe, CEP, 89500-199 Caçador, SC, Brazil.
Programa de Pós-Graduação em Ciências Farmacêuticas (PPGCF), Núcleo de Investigacões Químico-Farmacêuticas (NIQFAR), Universidade do Vale do Itajaí (UNIVALI), Rua Uruguai, 458, Centro, 88302-202 Itajaí, SC, Brazil.
Evid Based Complement Alternat Med. 2022 Apr 13;2022:6134128. doi: 10.1155/2022/6134128. eCollection 2022.
The focus of this study was to evaluate the gastric healing effect of lupeol stearate (LS) and its ability to minimize ulcer recurrence in rodents.
To evaluate the gastric healing properties of LS, rats were subjected to 80% acetic acid-induced ulcer model and treated with vehicle, LS (1 mg/kg, p.o.), or omeprazole (20 mg/kg, p.o.), twice daily by seven days. The gastric ulcers were evaluated macroscopically, histologically, and biochemically. To evaluate the effects of LS in gastric ulcer recurrence, mice were ulcerated with 10% acetic acid and treated with vehicle, LS (1 mg/kg, p.o.), or ranitidine (100 mg/kg, p.o.), twice a day for ten days. Then, ulcer recurrence in these animals was induced by IL-1 at five days after the treatment period.
The oral treatment with LS accelerated gastric healing by 63% in rats compared to the vehicle group, evidenced by histological improvement and increased gastric mucin levels. Moreover, the gastric healing effects of LS in rats were accompanied by an elevation in glutathione S-transferase activity and a reduction in myeloperoxidase activity. Furthermore, the LS treatment reduced the recurred lesions in mice.
The oral treatment of LS accelerates gastric healing in rats by favoring mucus production and reducing neutrophil migration, and it also can reduce ulcer recurrence. These data highlighted this compound as promising for developing new pharmacological strategies for the management of gastric ulcer.
本研究的重点是评估硬脂酸羽扇豆醇酯（LS）对啮齿动物的胃愈合作用及其降低溃疡复发的能力。
为评估LS的胃愈合特性，将大鼠制成80%乙酸诱导的溃疡模型，分别用赋形剂、LS（1毫克/千克，口服）或奥美拉唑（20毫克/千克，口服）治疗，每天两次，持续7天。对胃溃疡进行宏观、组织学和生化评估。为评估LS对胃溃疡复发的影响，用10%乙酸使小鼠产生溃疡，分别用赋形剂、LS（1毫克/千克，口服）或雷尼替丁（100毫克/千克，口服）治疗，每天两次，持续10天。然后，在治疗期结束5天后，用白细胞介素-1诱导这些动物溃疡复发。
与赋形剂组相比，口服LS使大鼠胃愈合加速了63%，组织学改善和胃黏液水平升高证明了这一点。此外，LS对大鼠的胃愈合作用伴随着谷胱甘肽S-转移酶活性升高和髓过氧化物酶活性降低。此外，LS治疗减少了小鼠的复发损伤。
口服LS通过促进黏液产生和减少中性粒细胞迁移加速大鼠胃愈合，还可降低溃疡复发。这些数据突出表明该化合物有望用于开发治疗胃溃疡的新药理学策略。
